F.V. VALEEVA¹, D.M. KRASIL’NIKOV^{1, 2}, L.T. BAREEVA², A.V. SHAKULO¹

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan

 Contact details:

Valeeva F.V. — MD, Professor, Head of the Endocrinology Department

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-917-255-55-79, e-mail: val_farida@mail.ru

In the recent decades the most acute issues are those of the timely diagnostics, development and introduction of prophylactics and treatment methods for complications which are associated with the intolerance of drugs used to normalize the thyroid gland function in thyrotoxicosis. The need to solve these problems is due to the frequency and severity of the disease course, requiring the use of radical treatment methods. This review provides the information about the side effects and complications of thyrostatic therapy.

Key words: Graves disease, thyrotoxicosis, side effects of thyrostatic treatment.

REFERENCES

1. Krasil’nikov D.M., Valeeva F.V., Bareeva L.T., Malova I.I., Kiseleva T.A. Kompleksnoe lechenie bol’nykh s bolezn’yu Greyvsa [Complex treatment of patients with Graves’ disease]. Sovremennye aspekty khirurgicheskoy endokrinologii: materialy XX Ros. simpoziuma s mezhdunar. uchastiem. Kazan, 2012. Pp. 151–156.
2. Okamura K., Sato K., Fujikawa M. et al. Remission after potassium iodide therapy in patients with Graves’ hyperthyroidism exhibiting thionamide-associated side effects. Journal of Clinical Endocrinology and Metabolism, 2014, vol. 99 (11), pp. 3995–4002.
3. Pestritskaya E.A. Vozmozhnosti personalizirovannoy radioyodterapii u bol’nykh s diffuznym toksicheskim zobom: avtoref. dis. … kand. med. nauk [Possibilities of personalized radioiodine therapy in patients with diffuse toxic goiter. Synopsis of dis. PhD med. sciences]. Moscow, 2017. Pp. 29–50.
4. Bahn R.S., Burch H.B., Cooper D.S. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of clinical endocrinologists. Endocr. Pract, 2011, vol. 17 (3), p. 65.
5. Fadeev V.V. Based on the clinical guidelines of the European Thyroid Association for the diagnosis and treatment of thyrotoxicosis in Graves’ disease 2018. Klinicheskaya i eksperimental’naya tireoidologiya, 2020, no. 16 (1), pp. 4–20 (in Russ.).
6. Pan’kov V.I. Thyrostatic drugs in the treatment of diffuse toxic goiter. Mezhdunarodnyy endokrinologicheskiy zhurnal, 2013, no. 3 (51), pp. 10–16 (in Russ.).
7. Petunina N.A., Trukhina L.V., Martirosyan N.S. Graves’ disease — unresolved issues in treatment. Doktor. Ru, 2014, no. 8 (96), part II, pp. 49–53 (in Russ.).
8. Troshina E.A., Sviridenko N.Yu., Vanushko V.E. et al. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu tireotoksikoza s diffuznym zobom (diffuznyy toksicheskiy zob, bolezn’ Greyvsa — Bazedova), uzlovym / mnogouzlovym zobom [Federal clinical guidelines for the diagnosis and treatment of thyrotoxicosis with diffuse goiter (diffuse toxic goiter, Graves-Basedow disease), nodular / multinodular goiter]. Moscow, 2014. 25 p.
9. Moysieva O.M., Muradov E.A. A clinical case of secondary agranulocytosis against the background of thyreostatic therapy in Graves’ — Basedow’s disease. Universitetskaya meditsina Urala, 2019, no. 1, pp. 89–91 (in Russ.).
10. Andersohn F., Konzen C., Garbe E. Systematic review: agranulocytosis induced by non-chemotherapy drugs. Ann Intern Med, 2007, vol. 146 (9), pp. 657–665.
11. Kobayashi S., Noh J.Y., Mukasa K. et al. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid, 2014, vol. 24 (5), pp. 796–801.
12. Bobrova E.I., Vinogradskaya O.I., Gubernatorova E.E. et al. Agranulocytosis induced by the intake of thyreostatics. Terapiya, 2020, vol. 6, no. 8 (42), pp. 162–167 (in Russ.).
13. Abraham P., Acharya S. Current and emerging treatment options for Graves’ hyperthyroidism. Ther. Clin. Risk Manag, 2010, vol. 6, pp. 29–40.
14. Fumarola A., Di Fiore A., Dainelli M. et al. Medical treatment of hyperthyroidism: state of the art. Exp. Clin. Endocrinol. Diabetes, 2010, vol. 118 (10), pp. 678–684.
15. Cooper D.S. Antithyroid drugs. New England Journal of Medicine, 2005, vol. 352 (9), pp. 905–917.
16. Braverman L.E., Utiger R.D. The thyroid: a fundamental and clinical text. 10th ed. Phylodelphia: Lippicott, Williams, Wilkins, 2012. 915 p.
17. Boxer L.A. How to approach neutropenia. Hematology Am SocHematol Educ Program., 2012, vol. 1, pp. 174–182.
18. Wondisford F.E., Radovick S. Clinical Management of Thyroid Disease. Baltimore, Maryland: Elsevier Inc., 2009. 860 p.
19. Ivanova S.N., Dvoryashina I.V. Leykopeniya i agranulotsitoz — oslozhneniya tireostaticheskoy terapii bolezni Greyvsa [Leukopenia and agranulocytosis — complications of thyreostatic therapy of Graves’ disease]. Sbornik tezisov VII Vserossiyskogo kongressa endokrinologov. Moscow: UP Print, 2016. 387 p.
20. Johnston A., Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol, 2015, vol. 11 (2), pp. 243–257.
21. Abramova N.A. Conservative treatment of Graves’ disease: principles, markers of relapse and remission. Problemy endokrinologii, 2005, vol. 51, no. 6, pp. 44–49 (in Russ.).
22. Tsuboi K., Ueshiba H., Shimojo M. et al. The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves’ disease. Endocr J., 2007, vol. 54 (1), pp. 39–43.
23. Petunina N.A. Conservative treatment of diffuse toxic goiter: opportunities, problems, solutions. Effektivnaya farmakoterapiya v endokrinologii, 2009, no. 3, pp. 14–20 (in Russ.).
24. Sakhipov D.R. Differentsirovannaya taktika pri khirurgicheskom lechenii bol’nykh s diffuznym toksicheskim zobom: avtoref. dis. … kand. med. nauk [Differentiated tactics in the surgical treatment of patients with diffuse toxic goiter. Synopsis of dis. PhD med. sciences]. Samara, 2016. Pp. 21–44.
25. Yang J., Zhu Y.J., Zhong J. et al. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid, 2016, vol. 26 (5), pp. 627–633.
26. Sheng W.H., Hung C.C., Chen Y.C. et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. QJM, 1999, vol. 92 (8), pp. 455–461.
27. Petunina N.A., Trukhina L.V., Martirosyan N.S. Graves’ disease: a modern perspective on treatment issues. Effektivnaya farmakoterapiya. Endokrinologiya, 2011, no. 3, pp. 24-28 (in Russ.).
28. Fukata S., Kuma K., Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid, 1999, vol. 9 (1), pp. 29–31.
29. Nakamura H., Miyauchi A., Miyawaki N. et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. Journal of Clinical Endocrinology and Metabolism, 2013, vol. 98 (12), pp. 4776–4783.
30. Watanabe N., Narimatsu H., Noh J.Y. et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50385 patients with Graves’ disease. Journal of Clinical Endocrinology and Metabolism, 2012, vol. 97 (1), pp. 49–53.
31. de Campos Mazo D.F., de Vasconcelos G.B., Pereira M.A. et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol, 2013, vol. 6 (1), pp. 9–17.
32. Wang M.T., Lee W.J., Huang T.Y. et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: apopulation-based cohort study. Br J Clin Pharmacol, 2014, vol. 78 (3), pp. 619–629.
33. Pikulev D.V., Klemenov A.V. Thyrotoxic hepatitis. Problemy endokrinologii, 2017, no. 63 (1), pp. 46–50 (in Russ.).
34. Shul’pekova Yu.O. Medicinal lesions of the liver, 2010, Zdorov’ya Ukraїni 21 storіchchya. Tematicheskiy nomer, pp. 24–25 (in Russ.), available at: Здоров’я https://health-ua.com/newspaper/med_gaz_zu України
35. Barzilay-Yoseph L., Shabun A., Shilo L. et al. Thyrotoxic hepatitis. Isr Med Assoc J,2011, vol. 13 (7), pp. 448–450.
36. Shetty S., Rajasekaran S., Venkatakrishnan L. Grave’s disease and primary biliary cirrhosis-an unusual and challenging association. J Clin Exp Hepatol, 2014, vol. 4 (1), pp. 66–67.
37. Kishore K., Adhya A.K. Graves’ disease with Pancytopenia and Hepatic Dysfunction: A Rare Case Presentation. Indian Journal of Nuclear Medicine, 2019, vol. 34, pp. 38–41.
38. Kubota S., Amino N., Matsumoto Y. et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by graves’ disease and painless thyroiditis. Thyroid, 2008, vol. 18 (3), pp. 283–287.
39. Breidert M., Offensperger S., Blum H.E. et al. Weight loss and severe jaundice in a patient with hyperthyroidism. Z Gastroenterol, 2011, vol. 49 (9), pp. 1267–1269.
40. Burra P. Liver abnormalities and endocrine diseases. Best Pract Res Clin Gastroenterol, 2013, vol. 27 (4), pp. 553–563.
41. Hsieh A., Adelstein S., Twigg S.M. Liver enzyme profile and progression in association with thyroid autoimmunity in Graves’ disease. Endocrinology, Diabetes and Metabolism, 2019, vol. 2 (4), pp. 1–7.
42. Khlynova O.V., Girfanova L.G. Clinical case of thyrotoxic hepatitis. Dokazatel’naya gastroenterologiya, 2020, vol. 9, no. 3, pp. 73–76 (in Russ.).
43. Neymark M.I. Sravnitel’naya otsenka razlichnykh metodov efferentnoy terapii v predoperatsionnoy podgotovke bol’nykh diffuznym toksicheskim zobom [Comparative evaluation of various methods of efferent therapy in the preoperative preparation of patients with diffuse toxic goiter]. Sovremennye aspekty khirurgicheskoy endokrinologii. Yaroslavl, 2004. Pp. 182–184.
44. Galyan A.N. Correction of thyroid status in the effectiveness of the perioperative period in patients with thyropathies. Sibirskiy meditsinskiy zhurnal, 2011, vol. 26, no. 4. – pp. 193–196 (in Russ.).
45. Oshikov O.Sh. Optimizatsiya predoperatsionnoy podgotovki bol’nykh s diffuznym toksicheskim zobom: avtoref. dis. … kand. med. nauk [Optimization of preoperative preparation of patients with diffuse toxic goiter. Synopsis of dis. PhD med. sciences]. Bishkek, 2011. 23 p.
46. El Fassi D., Clemmensen O., Nielsen C. H. et al. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease. J. Clin. Endocrinol. Metab, 2007, vol. 92 (10), pp. 3762–3763.
47. Salvi M., Vannucchi G., Campi I. et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol, 2007, vol. 156 (1), pp. 33–40.
48. Heyes C., Nolan R., Leahy M. et al. Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. The Australasian Journal of Dermatology, 2012, vol. 53 (1), pp. 1–4.
49. Kankara C.R., Browne D. Role of plasmapheresis in rapid preoperative stabilization of severe Grave’s thyrotoxicosis. Endocrine Abstracts, 2012, vol. 28, p. 58.
50. Frolkin A.P. Efferentnye tekhnologii v lechenii bol’nykh diffuznym toksicheskim zobom s neperenosimost’yu tireostaticheskikh preparatov: avtoref. dis. … kand. med. nauk [Efferent technologies in the treatment of patients with diffuse toxic goiter with intolerance to thyreostatic drugs. Synopsis of dis. PhD med. sciences]. Ulyanovsk, 2012. 21 p.
51. Vilkov A.V., Davydkin V.I., Golubev A.G. et al. Evaluation of the effectiveness of non-drug methods in the treatment of patients with diffuse toxic goiter. Klinicheskaya meditsina, 2019, no. 6, pp. 140–144 (in Russ.).
52. Kalinin A.P., Kamen’ev A.A., Yurina T.M. The value of plasmapheresis in surgery for toxic goiter. Gravitatsionnaya khirurgiya, 1983, no. 3, pp. 105–107 (in Russ.).
53. Piksin I.N. Sochetanie plazmafereza i eritrodesorbtsii gemodezom v lechenii bol’nykh diffuznym toksicheskim zobom [Combination of plasmapheresis and erythrodesorption by hemodesis in the treatment of patients with diffuse toxic goiter]. Sovremennye aspekty khirurgicheskoy endokrinologii. Yaroslavl, 2004. Pp. 198–200.
54. Rafibekov D.S. Plazmaferez s kriopretsipitatsiey plazmy v kompleksnoy predoperatsionnoy podgotovke bol’nykh diffuznym toksicheskim zobom [Plasmapheresis with plasma cryoprecipitation in complex preoperative preparation of patients with diffuse toxic goiter]. Sovremennye aspekty khirurgicheskoy endokrinologii. Yaroslavl, 2004. Pp. 334–336.
55. Neymark I.I., Dudarev V.A. Preoperative preparation by plasmapheresis of patients with diffuse toxic goiter with intolerance to antithyroid drugs. Problemy endokrinologii, 1986, no. 3, pp. 24–27 (in Russ.).
56. Pasimeni G., Caroli F., Spriano G. et al. Refractory thyrotoxicosis induced by iodinated contrast agents treated with therapeutic plasma exchange. A case report. Journal of Clinical Apheresis, 2008, vol. 23 (2), pp. 92–95.
57. Almeida R.F., Comarella A.P., Silveira M.B. et al. Plasmapheresis before thyroidectomy in a patient with thyrotoxicosis and hepatotoxicity by propylthiouracil: case report. Arquvios Brasileiros de Endocrinologia e Metabologia, 2013, vol. 57 (4), pp. 322–326.
58. Miljić D., Stojanović M., Ješić R. et al. Role of plasma exchange in autoimmune hyperthyroidism complicated by severe tiamazol-induced cholestatic jaundice. Transfusion and Apheresis Science, 2013, vol. 49 (2), pp. 354–356.
59. Min S.H., Phung A., Oh T.J. et al. Therapeutic Plasmapheresis Enabling Radioactive Iodine Treatment in a Patient with Thyrotoxicosis. Journal of Korean Medical Science, 2015, vol. 30 (10), pp. 1531–1534.
60. Komerdus I.V. Optimizatsiya lecheniya radioaktivnym yodom bol’nykh tireotoksikozom: avtoref. dis. … kand. med. nauk [Optimization of treatment with radioactive iodine in patients with thyrotoxicosis. Synopsis of dis. PhD med. sciences]. Moscow, 2008. 26 p.
61. Tsyb A.F., Dreval’ A.V., Garbuzov P.I. Radioyodterapiya tireotoksikoza: rukovodstvo [Radioiodine therapy for thyrotoxicosis: a guide]. Moscow: GEOTAR-Media, 2009. 160 p.
62. Burch H.B., Burman K.D., Cooper D.S. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J. Clin. Endocrinol. Metab, 2012, vol. 97 (12), pp. 4549–4558.
63. Bartalena L., Tanda M.L, Piantanida E. et al. Glucocorticoids and outcome of radioactive iodine therapy for Graves’ hyperthyroidism. Eur J Endocrinol, 2005, vol. 153, rr. 13–18.
64. Abalovich M., Amino N., Barbour L.A. et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab, 2007, vol. 92 (8), pp. 1–47.